Shionogi Highlights Japan’s Role in Advancing Global Health in Dialogue with Bill Gates - Discuss...

Shionogi Highlights Japan’s Role in Advancing Global Health in Dialogue with Bill Gates - Discussing the Fight Against Infectious Diseases and the Future of Sustainable Healthcare Models under the Theme “Japan’s Role in Advancing Global Health Progres  Shionogi Inc.

Shionogi to Acquire Japan Tobacco’s Pharmaceutical Business - TipRanks

Shionogi to Acquire Japan Tobacco’s Pharmaceutical Business  TipRanks

Is It Smart To Buy Shionogi & Co., Ltd. (TSE:4507) Before It Goes Ex-Dividend? - simplywall.st

Is It Smart To Buy Shionogi & Co., Ltd. (TSE:4507) Before It Goes Ex-Dividend?  simplywall.st

Can Shionogi’s Rally Continue After Key Drug Approval in 2025? - Yahoo Finance

Can Shionogi’s Rally Continue After Key Drug Approval in 2025?  Yahoo Finance

FDA Accepts Shionogi’s NDA for Ensitrelvir Oral Antiviral in COVID-19 Postexposure Prevention - C...

FDA Accepts Shionogi’s NDA for Ensitrelvir Oral Antiviral in COVID-19 Postexposure Prevention  Contagion Live

BioVersys and Shionogi agree to develop ansamycin leads - Pharmaceutical Technology

BioVersys and Shionogi agree to develop ansamycin leads  Pharmaceutical Technology

FDA Accepts Shionogi’s Ensitrelvir NDA for COVID PEP - Infectious Disease Special Edition

FDA Accepts Shionogi’s Ensitrelvir NDA for COVID PEP  Infectious Disease Special Edition

FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 F...

FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 Following Exposure  Business Wire

Shionogi Implements Stibo Systems MDM Solution - PR Newswire

Shionogi Implements Stibo Systems MDM Solution  PR Newswire

Shionogi to buy Japan Tobacco's pharma units for over $1B - FirstWord Pharma

Shionogi to buy Japan Tobacco's pharma units for over $1B  FirstWord Pharma

Shionogi Eyes US Plant to Boost Antibiotic Production Amid Tariffs Challenge - JAPAN Forward

Shionogi Eyes US Plant to Boost Antibiotic Production Amid Tariffs Challenge  JAPAN Forward

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Reaches New 12-Month High - What's Next? - M...

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Reaches New 12-Month High - What's Next?  MarketBeat

Accelerating drug discovery with AI innovation - SAS: Data and AI Solutions

Accelerating drug discovery with AI innovation  SAS: Data and AI Solutions

Shionogi puts more than $600M on the table for Swiss biotech's antibiotic program - Fierce Biotech

Shionogi puts more than $600M on the table for Swiss biotech's antibiotic program  Fierce Biotech

Sponsorship of the 25th Summer Deaflympics Tokyo 2025｜ 塩野義製薬 - Shionogi Inc.

Sponsorship of the 25th Summer Deaflympics Tokyo 2025｜ 塩野義製薬  Shionogi Inc.

Shionogi strikes research and option deal with BioVersys for antibacterial assets - FirstWord Pharma

Shionogi strikes research and option deal with BioVersys for antibacterial assets  FirstWord Pharma

Shionogi to Present New Data from Anti-Infective Portfolio at IDWeek - Business Wire

Shionogi to Present New Data from Anti-Infective Portfolio at IDWeek  Business Wire

Shionogi awarded $375m from HHS for preventative Covid-19 injectable - Pharmaceutical Technology

Shionogi awarded $375m from HHS for preventative Covid-19 injectable  Pharmaceutical Technology

Enrollment Update - Shionogi Inc.

Enrollment Update  Shionogi Inc.

Shionogi to acquire Japan Tobacco pharma companies for $1.1B - BioWorld MedTech

Shionogi to acquire Japan Tobacco pharma companies for $1.1B  BioWorld MedTech

Drugmaker Shionogi to buy Japan Tobacco's unit Torii Pharmaceutical for $1 billion - Reuters

Drugmaker Shionogi to buy Japan Tobacco's unit Torii Pharmaceutical for $1 billion  Reuters

Shionogi and UBE: Novel Antiviral Drug Demonstrates Efficacy in RSV Patients - 2 Minute Medicine

Shionogi and UBE: Novel Antiviral Drug Demonstrates Efficacy in RSV Patients  2 Minute Medicine

Shionogi Weighs Making Antibiotics in US Amid Rising Tariffs - Bloomberg.com

Shionogi Weighs Making Antibiotics in US Amid Rising Tariffs  Bloomberg.com

Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trial - Clinical Trials A...

Shionogi’s RSV antiviral reduces viral load in Phase II human challenge trial  Clinical Trials Arena

BioVersys joins forces with Shionogi on ansamycin development - The Pharma Letter

BioVersys joins forces with Shionogi on ansamycin development  The Pharma Letter

Shionogi strengthens position by acquiring Torii - MarketScreener

Shionogi strengthens position by acquiring Torii  MarketScreener

Shionogi's RSV antiviral reduces viral load in phase 2 trial of adults - Fierce Biotech

Shionogi's RSV antiviral reduces viral load in phase 2 trial of adults  Fierce Biotech

Shionogi puts up to $600m behind BioVersys antibiotics - pharmaphorum

Shionogi puts up to $600m behind BioVersys antibiotics  pharmaphorum

Shionogi pushes 2030 vision forward with $1 billion acquisition - The Pharma Letter

Shionogi pushes 2030 vision forward with $1 billion acquisition  The Pharma Letter

Clinigen and Shionogi CEOs meet for signing ceremony - European Pharmaceutical Manufacturer

Clinigen and Shionogi CEOs meet for signing ceremony  European Pharmaceutical Manufacturer

Bioversys, Shionogi in CHF529M lung infection collaboration - BioWorld MedTech

Bioversys, Shionogi in CHF529M lung infection collaboration  BioWorld MedTech

Clinigen and Shionogi formalize licensing pact for cefiderocol - The Pharma Letter

Clinigen and Shionogi formalize licensing pact for cefiderocol  The Pharma Letter

Development of a Manufacturing Process for S-892216 Part I: A Novel Method for Constructing a Mul...

Development of a Manufacturing Process for S-892216 Part I: A Novel Method for Constructing a Multi-Substituted Barbiturate Skeleton for Scalable Synthesis  ACS Publications

Shionogi Completes Acquisition of TORII PHARMACEUTICAL as Wholly-Owned Subsidiary - TipRanks

Shionogi Completes Acquisition of TORII PHARMACEUTICAL as Wholly-Owned Subsidiary  TipRanks

Transition of Promotional Activities for Allergen Immunotherapy Drug Actair® in Japan - Business ...

Transition of Promotional Activities for Allergen Immunotherapy Drug Actair® in Japan  Business Wire

Roche, Shionogi Patents Deal Delays Alvogen’s Copies of Flu Drug - Bloomberg Law News

Roche, Shionogi Patents Deal Delays Alvogen’s Copies of Flu Drug  Bloomberg Law News

The Leadership Connection - thebossmagazine.com

The Leadership Connection  thebossmagazine.com

BARDA’s $375M to Shionogi for COVID-19 tops early list of 2025 grants - BioWorld MedTech

BARDA’s $375M to Shionogi for COVID-19 tops early list of 2025 grants  BioWorld MedTech

Ceolia takes over from Shionogi in marketing of Actair in Japan - The Pharma Letter

Ceolia takes over from Shionogi in marketing of Actair in Japan  The Pharma Letter

Shionogi inks new hearing loss research deal with Cilcare - The Pharma Letter

Shionogi inks new hearing loss research deal with Cilcare  The Pharma Letter

Shionogi’s S-880008 shows broad range of activity against SARS-CoV-2 variants - BioWorld MedTech

Shionogi’s S-880008 shows broad range of activity against SARS-CoV-2 variants  BioWorld MedTech

Bristol Myers’ $40B US investment; Shionogi to buy Japanese drugmaker - Endpoints News

Bristol Myers’ $40B US investment; Shionogi to buy Japanese drugmaker  Endpoints News

Eyes on Asia: Chugai, Mabwell, Shionogi - BioXconomy

Eyes on Asia: Chugai, Mabwell, Shionogi  BioXconomy

Shionogi aims to buy tobacco giant's pharma unit for $1bn - pharmaphorum

Shionogi aims to buy tobacco giant's pharma unit for $1bn  pharmaphorum

Action to Implement Management that is Conscious of Cost of Capital and Stock Price | IR Library ...

Action to Implement Management that is Conscious of Cost of Capital and Stock Price | IR Library | Shionogi & Co., Ltd.  Shionogi Inc.

Pharmalittle: We're reading about conflicts on U.S. vaccine panels, pharma DTC sales, and much mo...

Pharmalittle: We're reading about conflicts on U.S. vaccine panels, pharma DTC sales, and much more  statnews.com

What drives Shionogi Co Ltd SH0 stock price - Risk-Reward Ratio Analysis & Free High Frequency Tr...

What drives Shionogi Co Ltd SH0 stock price - Risk-Reward Ratio Analysis & Free High Frequency Trading Ideas  earlytimes.in

Swiss firm BioVersys signs deal with Shionogi for antibiotics research - SWI swissinfo.ch

Swiss firm BioVersys signs deal with Shionogi for antibiotics research  SWI swissinfo.ch

Japan's Shionogi plans US antibiotic plant with eye on Trump tariffs - Nikkei Asia

Japan's Shionogi plans US antibiotic plant with eye on Trump tariffs  Nikkei Asia

Shionogi & Co. Reports Strong Q1 2025 Earnings Growth - The Globe and Mail

Shionogi & Co. Reports Strong Q1 2025 Earnings Growth  The Globe and Mail

Shionogi Receives Award Through BARDA's Rapid Response Partnership Vehicle to Advance Long-Acting...

Shionogi Receives Award Through BARDA's Rapid Response Partnership Vehicle to Advance Long-Acting Formulation of S-892216, an Antiviral for COVID-19 Pre-Exposure Prophylaxis in At-Risk Populations  Business Wire

Shionogi files in Japan to expand pediatric use of COVID-19 antiviral - The Pharma Letter

Shionogi files in Japan to expand pediatric use of COVID-19 antiviral  The Pharma Letter

Shionogi Falls on Report of $1 Billion Offer to Buy Torii Pharma - Bloomberg.com

Shionogi Falls on Report of $1 Billion Offer to Buy Torii Pharma  Bloomberg.com

Apnimed Provides Clinical Updates for Multiple Product Candidates - PR Newswire

Apnimed Provides Clinical Updates for Multiple Product Candidates  PR Newswire

BioVersys inks deal worth CHF 479 M with Japan's Shionogi to treat infectious diseases - BioSpect...

BioVersys inks deal worth CHF 479 M with Japan's Shionogi to treat infectious diseases  BioSpectrum Asia

Shionogi gets approval in Japan for ADHD digital therapeutic - pharmaphorum

Shionogi gets approval in Japan for ADHD digital therapeutic  pharmaphorum

His daughter has an ultra-rare genetic disorder. His push to treat it just hit a major milestone ...

His daughter has an ultra-rare genetic disorder. His push to treat it just hit a major milestone  CalMatters

Japan's Shionogi announces further agreement with Apnimed for sleep disorder treatments - BioSpec...

Japan's Shionogi announces further agreement with Apnimed for sleep disorder treatments  BioSpectrum Asia

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops - insights.citeline.com

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops  insights.citeline.com

Japan's Shionogi to acquire Torii Pharmaceutical from Japan Tobacco for $1 billion - MLex

Japan's Shionogi to acquire Torii Pharmaceutical from Japan Tobacco for $1 billion  MLex

Nxera and Shionogi launch Quviviq in Japan - The Pharma Letter

Nxera and Shionogi launch Quviviq in Japan  The Pharma Letter

Ironwood’s layoffs; Shionogi’s RSV pill succeeds in Phase 2 - Endpoints News

Ironwood’s layoffs; Shionogi’s RSV pill succeeds in Phase 2  Endpoints News

Japan's Shionogi inks new partnership agreement to support antimicrobial stewardship in Kenya - B...

Japan's Shionogi inks new partnership agreement to support antimicrobial stewardship in Kenya  BioSpectrum Asia

Shionogi inks commercial deal for Cefiderocol in Australia and New Zealand - BioSpectrum Asia

Shionogi inks commercial deal for Cefiderocol in Australia and New Zealand  BioSpectrum Asia

Japanese drugmaker Shionogi to acquire JT's pharma units in $1.1bn deal - Nikkei Asia

Japanese drugmaker Shionogi to acquire JT's pharma units in $1.1bn deal  Nikkei Asia

Japan's Shionogi says Phase 3 study showed COVID pill reduces transmission - Reuters

Japan's Shionogi says Phase 3 study showed COVID pill reduces transmission  Reuters

China’s Ping An Insurance Wraps Up Exit From Joint Venture With Japanese Drug Giant Shionogi - Yi...

China’s Ping An Insurance Wraps Up Exit From Joint Venture With Japanese Drug Giant Shionogi  Yicai Global

A Pill to Prevent COVID-19 Shows Promise - Time Magazine

A Pill to Prevent COVID-19 Shows Promise  Time Magazine

Shionogi and Jordan’s Guardian Angels Announce First-Ever Human Drug Study for Jordan’s Syndrome,...

Shionogi and Jordan’s Guardian Angels Announce First-Ever Human Drug Study for Jordan’s Syndrome, an Ultra-Rare Genetic Neurodevelopmental Disorder  BioSpace

Antibiotics business model should be the flipside of pharma norm, says Shionogi Europe CEO - Eura...

Antibiotics business model should be the flipside of pharma norm, says Shionogi Europe CEO  Euractiv

Shionogi's Xocova hits bullseye in COVID-19 post-exposure prophylaxis study - FirstWord Pharma

Shionogi's Xocova hits bullseye in COVID-19 post-exposure prophylaxis study  FirstWord Pharma

Nxera Pharma and Shionogi Launch QUVIVIQ in Japan for Insomnia Treatment - Precedence Research

Nxera Pharma and Shionogi Launch QUVIVIQ in Japan for Insomnia Treatment  Precedence Research

First-Generation Process Development for the Synthesis of Baloxavir Marboxil: Early-Stage Develop...

First-Generation Process Development for the Synthesis of Baloxavir Marboxil: Early-Stage Development of Synthetic Methods to Prepare Baloxavir Marboxil Intermediates  ACS Publications

Shionogi’s ensitrelvir prevents symptomatic COVID-19 - The Pharma Letter

Shionogi’s ensitrelvir prevents symptomatic COVID-19  The Pharma Letter

Notice of Head Office Relocation｜ 塩野義製薬 - Shionogi Inc.

Notice of Head Office Relocation｜ 塩野義製薬  Shionogi Inc.

Japan's Shionogi inks agreement with Osaka Metropolitan University to establish model for city re...

Japan's Shionogi inks agreement with Osaka Metropolitan University to establish model for city resilient to infectious diseases  BioSpectrum Asia

NIH trial to evaluate Shionogi antiviral in adults hospitalized with COVID-19 - National Institut...

NIH trial to evaluate Shionogi antiviral in adults hospitalized with COVID-19  National Institutes of Health (NIH) | (.gov)

Launch of the Third Phase for the Mother to Mother SHIONOGI Project New Activities to Support Mat...

Launch of the Third Phase for the Mother to Mother SHIONOGI Project New Activities to Support Maternal and Child Health in Kenya and Ghana  Shionogi Inc.

Merging with the US biotech venture Qpex: A chronicle of striving for the integration process aim...

Merging with the US biotech venture Qpex: A chronicle of striving for the integration process aimed at maximizing value  Shionogi Inc.

SHIONOGI’s Commitment to Antibiotics: Aiming for an Ideal Collaboration between Industry, Governm...

SHIONOGI’s Commitment to Antibiotics: Aiming for an Ideal Collaboration between Industry, Government, and Academia to Tackle Infectious Diseases  Shionogi Inc.

Pharma sector sees $6.96 billion in global deal activity in May 2025, led by GSK, Shionogi, and E...

Pharma sector sees $6.96 billion in global deal activity in May 2025, led by GSK, Shionogi, and Eli Lilly: GlobalData  Express Pharma

Leveraging Real-world Data and Artificial Intelligence: The Story Behind the Outstanding Leadersh...

Leveraging Real-world Data and Artificial Intelligence: The Story Behind the Outstanding Leadership Award  Shionogi Inc.

Financial Highlights - Shionogi Inc.

Financial Highlights  Shionogi Inc.

Message from Top Management - Shionogi Inc.

Message from Top Management  Shionogi Inc.

Researchers on One Health and the Proper Use of Medications: Behind the Scenes of Rare Species Co...

Researchers on One Health and the Proper Use of Medications: Behind the Scenes of Rare Species Conservation and Infectious Disease Control｜ SHIONOGI  Shionogi Inc.

“Pharmaceutical Education” by Virtual Employee - Shionogi Inc.

“Pharmaceutical Education” by Virtual Employee  Shionogi Inc.

What we stand for: Takeki Uehara - Shionogi Inc.

What we stand for: Takeki Uehara  Shionogi Inc.

Shionogi to acquire Qpex Biopharma for $140m - Pharmaceutical Technology

Shionogi to acquire Qpex Biopharma for $140m  Pharmaceutical Technology

Nathan McCutcheon - Shionogi Inc.

Nathan McCutcheon  Shionogi Inc.

Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Insomnia - The Manila Times

Nxera Pharma and Shionogi Launch QUVIVIQ™ in Japan for Adults with Insomnia  The Manila Times

History - Shionogi Inc.

History  Shionogi Inc.

Shionogi presents pivotal ensitrelvir fumaric acid Phase 3 data and exploratory long COVID data -...

Shionogi presents pivotal ensitrelvir fumaric acid Phase 3 data and exploratory long COVID data  European AIDS Treatment Group

Antimicrobial resistance: Shionogi advocates policy change to address the public health threat - ...

Antimicrobial resistance: Shionogi advocates policy change to address the public health threat  Nature

Shionogi enrols first subject in SARS-CoV-2 therapy trial in Japan - Clinical Trials Arena

Shionogi enrols first subject in SARS-CoV-2 therapy trial in Japan  Clinical Trials Arena

Japan's Shionogi says COVID-19 pill shows rapid clearance of virus - Reuters

Japan's Shionogi says COVID-19 pill shows rapid clearance of virus  Reuters

Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial - Reuters

Japan's Shionogi says COVID treatment did not meet endpoint in late-stage trial  Reuters

Japan to grant emergency approval to Shinogi COVID-19 drug - Reuters

Japan to grant emergency approval to Shinogi COVID-19 drug  Reuters

Shionogi secures license for Maze’s Pompe disease treatment - Pharmaceutical Technology

Shionogi secures license for Maze’s Pompe disease treatment  Pharmaceutical Technology

After FTC stalled Sanofi deal, Shionogi secures Maze's Pompe disease drug for $150M - Fierce Biotech

After FTC stalled Sanofi deal, Shionogi secures Maze's Pompe disease drug for $150M  Fierce Biotech

Shionogi sinks in Tokyo trade after panel again delays COVID pill approval - Reuters

Shionogi sinks in Tokyo trade after panel again delays COVID pill approval  Reuters